Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
221
resultados
Última actualización
12/12/2025 [06:58:00]
Resultados 125 a 150 de 221
Resumen de: CN121041239A
本发明公开一种用于靶向蛋白降解的纳米颗粒及降解方法。本发明的纳米颗粒能够增强细胞的摄取，并对识别目标蛋白的特异性抗体实现有效地包封，同时干扰素组分可以诱导细胞内TRIM家族蛋白的表达。在被摄取入胞后，纳米颗粒释放的抗体可以结合目标蛋白，并结合TRIM家族蛋白介导目标蛋白的降解。在这一过程中，TRIM家族蛋白虽然被持续消耗，但可以被本发明的颗粒所诱导的TRIM家族蛋白表达所补偿，从而维持了高效的降解。
Resumen de: CN121041240A
为本发明属于纳米生物材料技术领域，公开了一种负载二氢杨梅素的白桦脂酮酸自组装纳米复合体系的制备方法和应用，所述纳米复合体系为白桦脂酮酸为载体，二氢杨梅素为活性成分的纳米复合体系。本发明制备的纳米组装体系的组装机制为：二氢杨梅素分子的酚羟基与白桦脂酮酸分子中的羰基和白桦脂酮酸分子中的羧基中的羰基结合产生的氢键相互作用为主要的非共价相互作用力。该纳米复合体系具有良好的生物相容性，且HT‑29细胞对纳米复合体系具有良好的摄取效果。在纳米生物材料领域具有一定的研究和应用前景。
Resumen de: CN121041432A
本发明涉及近红外二区有机染料技术领域，尤其涉及一种负载近红外二区氧杂蒽染料和热休克蛋白抑制剂的人血清白蛋白纳米复合物、制备方法及温和光热治疗肿瘤应用。该纳米复合物包括人血清白蛋白、NIR‑II氧杂蒽染料LD和热休克蛋白90抑制剂格尔德霉素，三者质量比为20:1:0.65。该纳米复合物具有较高的NIR‑II荧光/光声成像分辨率和信噪比，可实现增强的温和光热治疗肿瘤，为肿瘤的温和光热治疗提供了一种安全、高效、精准的全新策略，具有显著的临床转化潜力。
Resumen de: CN121041238A
本发明涉及纳米药物技术领域，尤其涉及可用于治疗脓毒症的唾液酸修饰依鲁替尼磷脂复合物纳米粒。本发明制备了一种唾液酸修饰依鲁替尼磷脂复合物纳米粒，其包括依鲁替尼、蛋黄磷脂酰甘油以及唾液酸‑胆固醇衍生物，该纳米粒能够显著提高制剂在炎症部位的积累和对“炎症相关巨噬细胞”的靶向，从而极大地提高了BTK抑制剂治疗脓毒症的有效性与安全性，更为重要的是，能够帮助脓毒症幸存小鼠解除免疫抑制状态，并产生强免疫记忆，极大地降低再感染风险，对解决临床中脓毒症幸存者出院后死亡率较高的难题具有指导意义；同时，本发明的唾液酸修饰依鲁替尼磷脂复合物纳米粒也能够降低机体对含有LPS抗原的病原体所致疾病的二次感染的风险。
Resumen de: CN121045032A
本发明涉及含有精氨酸结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途。具体地，提供一种式(1)所示的含有精氨酸及其衍生物结构的可电离脂质分子、包含其的脂质纳米颗粒、其制备方法和用途。与本领域常规使用的可电离脂质分子相比，本发明的式(1)所示的可电离脂质分子所制备得到的脂质纳米颗粒可实现核酸的高效率递送及表达。
Resumen de: CN121046378A
本发明提供了一种靶向Janus激酶1(JAK1)的干扰RNA，该干扰RNA可以降低JAK1的表达，进而抑制JAK/STAT信号通路的激活，从而达到治疗JAK/STAT信号通路失调的相关疾病。本发明还提供了一种包含干扰RNA的脂质纳米颗粒药物，用于治疗JAK/STAT信号通路失调的相关疾病。本发明还提供了一种抗体‑核酸偶联药物，其中包含干扰RNA，用于治疗JAK/STAT信号通路失调的相关疾病。
Resumen de: CN121041306A
本发明提供一种核酸纳米药物的制备及增敏肝癌免疫治疗疗效的应用，涉及生物医药技术领域。该核酸纳米药物通过PLGA‑S‑S‑PEG载体包载TMCO1及LONP1s i RNA，可在肿瘤细胞内高GSH环境下释放s i RNA，沉默靶基因并诱导免疫原性死亡，显著增强免疫检查点抑制剂的治疗效果。体内外实验表明，该纳米药物具有靶向性强、增敏效果显著、制备成本低等优势，为肝癌免疫治疗提供了新策略。
Resumen de: CN121041305A
本发明涉及了骨关节炎药物技术领域，具体公开了DDX5‑K45mRNA在制备治疗和/或缓解骨关节炎药物中的应用，同时提供了一种用于靶向软骨细胞的递药系统，研究发现，DDX5‑K45mRNA加入软骨细胞，可恢复DDX5‑K45乳酸化同时阻断NF‑κB炎症信号、纠正代谢重编程(如抑制异常糖酵解)、并上调COL2A1等软骨保护因子。本发明利用LNP高效递送DDX5‑K45mRNA至软骨细胞，直接补充内源性乳酸化修饰缺陷，重建DDX5的软骨保护功能，抑制炎症反应并减少基质降解，从根源上维持软骨稳态，实现长效、安全的OA治疗。
Resumen de: CN121041241A
本发明提供了一种双基因沉默、cRGD修饰的靶向LNP制备，及其在结直肠癌抗血管生成治疗中的应用；所述LNP由脂质原料和核酸原料制得；其中，脂质原料包括可电离阳离子脂质SM‑102、胆固醇、DOPE 磷脂、DMG‑PEG2000和DMG‑PEG2000‑cRGD，核酸原料包括siEIF3a与siVEGF；制备时，将脂质溶于乙醇、核酸溶于缓冲液后混匀静置。本发明通过cRGD靶向修饰结合双siRNA共递送实现，既依托cRGD提升LNP对结直肠癌细胞的靶向性与摄取效率，又通过双siRNA分别作用于VEGF通路与EIF3a‑ANG轴，针对性解决现有技术无法有效突破的结直肠癌抗血管生成治疗耐药问题。
Resumen de: CN121046392A
本发明提供了一种编码PTEN的环状RNA及其组合物的应用。本发明进一步涉及前述环状RNA联合免疫检查点抑制剂的组合物在肿瘤治疗中的应用。体内外药效学实验证明编码PTEN的环状RNA及其组合物可以有效抑制肿瘤生长，并且在与免疫检查点抑制剂联用时可以实现更好的药效。
Resumen de: AU2024212425A1
Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, glucosyl cholesterol; and modified by (b) an ionizable lipid. The disclosure also includes a method for making a modified lipid composition, comprising reconstructing (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, and/or glucosyl cholesterol in the presence of (b) an ionizable lipid, to produce the modified lipid composition, and loading into the modified lipid composition with one or more heterologous functional agents.
Resumen de: CN121041417A
本发明公开了一种棘球蚴病mRNA疫苗及其制备方法与应用。所述棘球蚴病mRNA疫苗的制备方法包括如下步骤：将改造的目标抗原蛋白进行密码子优化后，与5'UTR、3'UTR和Poly(A)尾进行组装，并进行基因合成，然后将合成的基因克隆至pUC57质粒中，并将构建得到的重组质粒依次进行质粒线性化、体外转录和纯化，制备得到mRNA分子，最后通过微流控方法将mRNA分子包裹于脂质纳米颗粒内形成棘球蚴病mRNA疫苗，并对其进行了免疫效果评价。通过实验证明：本发明制备的棘球蚴病mRNA疫苗能同时激活小鼠的体液免疫和细胞免疫，可为攻虫小鼠提供有效的保护作用，在预防和/或治疗棘球蚴病方面具有广阔的应用前景。
Resumen de: CN121041418A
本发明公开了一种棘球蚴病SaRNA疫苗及其制备方法与应用。所述SaRNA疫苗的制备方法包括如下步骤：通过基因工程技术将改造的目标抗原蛋白进行密码子优化后，与自复制蛋白序列以及5'UTR、3'UTR和Poly(A)尾进行组装，并进行基因合成，然后将合成的基因克隆到质粒中，并将构建得到的重组质粒依次进行质粒线性化、体外转录和纯化，制备得到SaRNA分子，最后将SaRNA分子包裹于脂质纳米颗粒内形成棘球蚴病SaRNA疫苗。实验证明：SaRNA疫苗能同时激活小鼠的体液免疫和细胞免疫，且低剂量免疫就能产生较高水平的EG95特异性抗体和细胞因子，在预防和/或治疗棘球蚴病方面具有广阔的应用前景。
Resumen de: CN121040616A
本发明公开了一种用于番茄红素递送的淀粉样β‑乳球蛋白纤维‑岩藻多糖自组装复合物的制备方法及应用，包括以下步骤：S1.将β‑LG溶解在去离子水中，配制1‑20 mg/mL浓度的β‑LG溶液，并搅拌 2 小时，并用1 mol/L的HCl溶液将β‑LG溶液调节至pH 2.0，得A品；S2.将A品置于石英容器中的两个电极之间反应，在室温下进行CP处理，得B品；S3.将B品在85°C水浴中进一步处理10小时制得C品，并立即在冰水中冷却C品，C品在4°C的温度下保存。它制备的淀粉样β‑乳球蛋白纤维‑岩藻多糖自组装复合物能有效提高番茄红素递送时的热稳定性和紫外稳定性，提高番茄红素递送效果。
Resumen de: MX2025013065A
Suspension formulations of nanoparticles of clobetasol propionate are described. The suspensions can be used therapeutically to treat skin and ocular burns; to enhance wound healing; to prevent or reduce hypertrophic scarring/keloids; to treat allergic rhinitis/sinusitis, asthma, inner ear disorders including hearing loss, tinnitus, or vertigo, tenosynovitis, tendinitis, enthesitis or arthritis.
Resumen de: MX2025013218A
Compounds are provided having the following Structure (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R<sup>1</sup>, R<sup>1</sup>, L<sup>1</sup>, L<sup>2</sup>, L<sup>2a</sup>, L<sup>2b</sup>, and A are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: MX2025013689A
The invention relates to novel compounds having a structure as set forth in any one of Formulas I, Ia, II, IIa, III, IIIa, IV or IVa, as described herein, and formulations comprising such novel compounds. The novel compounds and formulations of the invention may be useful in vaccine compositions. In some embodiments, the invention relates to compositions comprising at least one antigen and compounds having a structure as set forth in any one of Formulas I, Ia, II, IIa, III, IIIa, IV or IVa, as described herein, or pharmaceutically acceptable salt(s) thereof, wherein the compositions are prepared as stable nanoemulsions (herein referred to as "SNE adjuvant compositions" or "SNEs").
Resumen de: MX2025013363A
The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof:
Resumen de: MX2022006033A
Provided herein are ionizable lipids represented by the Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R1', R2', R3', R4', R5',R6', m, and n are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising an ionizable lipid of the invention and a capsid-free, non-viral vector (e.g., ceDNA). These LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
Resumen de: AU2023440872A1
The present invention provides an amino lipid, and lipid nanoparticles (LNPs) and a use thereof, the amino lipid having a structure represented by general formula (I), or an isomer, pharmaceutically acceptable salt, prodrug or solvate of the amino lipid. The present invention further provides LNPs containing the amino lipid. According to the present invention, the amino lipid having a structure represented by general formula (I) is used as an ionizable lipid compound, and the LNPs are obtained by means of self-assembly of the ionizable lipid compound, a steroid, a neutral lipid, and a polymer-bonded lipid. The LNPs can further improve the translation expression level of a nucleic acid load in cells, improve the effect of a nucleic acid-LNP preparation, and enable the nucleic acid-LNP preparation to provide a theoretical basis for personalized treatment.
Resumen de: AU2024252577A1
Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.
Resumen de: AU2024256347A1
The present disclosure is directed to the use of reconstituted mRNA dry powder particles for parenteral administration. The present disclosure is also directed to a method of generating dry powder particles supplemented with appropriate excipients for optimal thermostability and in vivo expression.
Resumen de: AU2024252371A1
The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g.. a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.
Resumen de: AU2024259356A1
The present disclosure describes compositions, nanoparticles (such as lipid nanoparticles), and/or lipid nanoparticle compositions and methods of their use.
Nº publicación: IL324243A 01/12/2025
Solicitante:
QUANTOOM BIOSCIENCES S A [BE]
QUANTOOM BIOSCIENCES S.A
Resumen de: WO2024223952A1
The current invention relates to a delivery system to deliver one or more cargo to one or more cells, wherein the cargo delivery system comprises at least a calixarene, a phospholipid, an additional lipid such as sterol. The invention further relates to a method of delivering cargo to a subject using the delivery system and a pharmaceutical composition comprising the delivery system. The invention also relates to the use of a calixarene in an immunogenic composition, wherein said composition comprises an immunogenic component encapsulated in a lipid nanoparticle (LNP) comprising said calixarene and wherein said LNP has an adjuvant effect in said immunogenic composition. The invention also relates to a vaccine, wherein said vaccine comprises an immunogenic component encapsulated in a lipid nanoparticle, wherein said lipid nanoparticle comprises at least one calixarene molecule and said lipid nanoparticle acts as an adjuvant in said vaccine. The invention also relates to a method of preparing an immunogenic composition and a composition comprising a lipid nanoparticle (LNP) adjuvant comprising calixarene.
BOPI
Sede Electrónica
